Bristol-Myers Squibb CEO Giovanni Caforio has friends on TV now. R&D chief Tom Lynch has done some of his CAR-T due diligence on YouTube. And one reason Celgene was interested in Bristol’s $ 74 billion buyout bid is that its own rollout of multiple sclerosis drug Otezla was, well, pretty lame. A fly on the… Read More »
Times Insider explains who we are and what we do, and delivers behind-the-scenes insights into how our journalism comes together. When some of my colleagues at The New York Times approached me about doing a health program for our readers, I knew immediately what I didn’t want. I didn’t want another impossible fitness program. (Some… Read More »
Unsophisticated drinking moments from the internet will be brought to life across the country through a series of augmented reality displays in bars and city centres — in a hi-tech bid to stop young adults getting too sozzled this Christmas. As silly season begins, Melbourne will be the first Aussie city to be hit by… Read More »
A Texas man facing 99 years in prison for a crime he didn’t commit credits a selfie for saving him. When cops showed up at Christopher Precopia’s work at a lumberyard in Georgetown in September 2017 to arrest him for burglary with the intent to commit other crimes, he was stunned, KVUE reported. “I had… Read More »